Lung Cancer Liquid Biopsy Market to Reach US$ 1,900.5 Million by 2032, Says Persistence Market Research

The lung cancer liquid biopsy market is poised for significant growth, with the market size expected to reach US$ 1,900.5 million by 2032, from US$ 824.7 million in 2025, growing at a CAGR of 12.7% during the forecast period. The rapid adoption of non-invasive diagnostic techniques is driving this expansion, as liquid biopsies offer a safer and less painful alternative to traditional tissue biopsies. By analyzing biomarkers present in blood samples, liquid biopsies detect lung cancer early, enabling more personalized treatment options.

One of the key growth drivers behind the market is the increasing prevalence of lung cancer globally. With rising incidences of lung cancer cases, especially non-small cell lung cancer (NSCLC), the demand for advanced diagnostic methods is escalating. Liquid biopsy tests are emerging as critical tools in identifying early-stage cancers, assessing treatment responses, and helping clinicians personalize therapeutic strategies. The integration of cutting-edge technologies, such as next-generation sequencing (NGS) and digital PCR, has further bolstered the appeal of liquid biopsy in clinical settings.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35195

Key Highlights from the Report:

➤ The lung cancer liquid biopsy market is forecasted to grow at a CAGR of 12.7% from 2025 to 2032.
➤ NGS-based multi-gene parallel analysis held a dominant market share in 2024, driving comprehensive genomic profiling.
➤ North America led the market in 2024, fueled by advanced healthcare infrastructure and high lung cancer prevalence.
➤ New technologies, such as Whole Genome Amplification (WGA) and Digital PCR, are enhancing detection precision.
➤ MicroRNAs are being explored as potential biomarkers for early detection of lung cancer.
➤ Asia Pacific is a fast-growing region, with China and Japan at the forefront of adoption.

Market Segmentation

The lung cancer liquid biopsy market is segmented based on product type, technology, and end-users. Consumables, kits, and reagents constitute a substantial portion of the market, accounting for 71.2% of revenue share in 2024. These consumables are critical in the diagnostic process, as they facilitate the collection, processing, and analysis of biological samples. The growing adoption of liquid biopsy tests for lung cancer detection is expected to drive the demand for these consumables further.

In terms of technology, next-generation sequencing (NGS) dominated the market with a 75.2% share in 2024. NGS allows for parallel analysis of multiple genetic mutations in lung cancer patients, providing high-throughput sequencing that leads to precise and personalized treatment regimens. This technology is increasingly used for identifying gene mutations such as EGFR mutations, KRAS mutations, and ALK rearrangements, which are crucial for selecting appropriate therapies for patients with NSCLC.

✅Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/lung-cancer-liquid-biopsy-market.asp

Regional Insights

North America

North America holds the largest market share, accounting for 47.8% of the total in 2024. The region's robust healthcare infrastructure and the increasing demand for advanced diagnostic methods drive market growth. In the U.S., lung cancer is one of the leading causes of cancer-related deaths, with over 226,650 new cases projected in 2025. The rising prevalence, combined with the growing demand for non-invasive diagnostic tools, positions North America as a dominant player in the lung cancer liquid biopsy market.

Europe

Europe is the second-largest market for lung cancer liquid biopsy, contributing 28.6% of the global market in 2024. The region is witnessing an increasing preference for non-invasive diagnostic methods, with significant investments aimed at developing and commercializing liquid biopsy technologies. European nations, such as Germany and the U.K., have robust healthcare systems that support the integration of liquid biopsy tests into clinical practices, making them key contributors to the market's growth.

Market Drivers

Several factors are propelling the growth of the lung cancer liquid biopsy market. Advances in liquid biopsy technologies and the discovery of new biomarkers are playing pivotal roles. New technologies like NGS and digital PCR allow for precise genomic profiling, enabling the identification of multiple genetic mutations that are critical for personalized treatment. Furthermore, the increasing prevalence of lung cancer is contributing to the demand for early detection tools, with liquid biopsy providing a promising solution for identifying cancer at its earliest stages.

In addition, initiatives like BioMark Diagnostics' lung cancer screening study in Quebec and Freenome's PROACT LUNG clinical study are accelerating the development and validation of liquid biopsy tests. These studies combine biomarkers with other technologies to enhance the accuracy and accessibility of lung cancer detection.

Market Restraints

Despite the promising growth prospects, the lung cancer liquid biopsy market faces certain challenges. One of the primary constraints is the limited sensitivity of biomarkers in detecting early-stage cancers. In the initial stages of lung cancer, the concentration of biomarkers such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) is often low, which complicates early detection. Additionally, the complexity and diversity of tumor biology further complicate the detection process, leading to variability in biomarker expression.

Moreover, the high costs of liquid biopsy tests, particularly those involving advanced technologies like NGS, may hinder their widespread adoption, especially in lower-income regions or countries with limited healthcare infrastructure.

Market Opportunities

The growing demand for liquid biopsy as a companion diagnostic tool presents a significant opportunity for market players. As more targeted therapies are developed for lung cancer, liquid biopsy tests that identify specific mutations (such as EGFR and ALK inhibitors) can help clinicians determine which patients are most likely to benefit from these treatments. This precision medicine approach enhances the value of liquid biopsy, both in clinical diagnostics and personalized treatment strategies.

Furthermore, the reduction in the cost of NGS technologies is opening up new opportunities for integrating liquid biopsy into routine clinical practices. As the cost of sequencing continues to fall, liquid biopsy has the potential to become a standard tool for early cancer detection, particularly in high-risk populations.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35195

Reasons to Buy the Report

✔ Gain insights into market trends and growth drivers for lung cancer liquid biopsy.
✔ Understand the competitive landscape and key players in the market.
✔ Evaluate regional market dynamics and their impact on the global market.
✔ Learn about the latest technological advancements in liquid biopsy and their role in lung cancer diagnosis.
✔ Access in-depth market segmentation analysis, providing valuable insights into specific product and technology categories.

Company Insights

The lung cancer liquid biopsy market is highly competitive, with several companies leading the charge in innovation and product development. Some of the key players operating in the market include:

✦ Guardant Health, Inc.
✦ Bio-Rad Laboratories, Inc.
✦ Freenome Holdings, Inc.
✦ Thermo Fisher Scientific Inc.
✦ Illumina, Inc.
✦ QIAGEN
✦ Oncocyte Corporation
✦ BioMark Diagnostics

Recent Developments:

In January 2025, Viz.ai partnered with Guardant Health to combine AI and genomics for enhanced lung cancer detection through the Viz.ai One platform.

In December 2024, Guardant Health teamed up with Boehringer Ingelheim to seek regulatory approval for the Guardant360® CDx liquid biopsy as a companion diagnostic tool for targeted NSCLC therapies.

Conclusion

The lung cancer liquid biopsy market is poised for significant growth, driven by technological advancements, increasing demand for non-invasive diagnostic tools, and the rise in lung cancer cases globally. While challenges like the limited sensitivity of biomarkers and high costs persist, the opportunities for liquid biopsy as a precision medicine tool and companion diagnostic are immense. With major players focusing on innovation and research collaborations, the market is expected to continue its upward trajectory, offering promising solutions for early cancer detection and personalized treatment in the coming years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.